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Afferent nerve sensitivity is decreased by an iNOS-dependent
mechanism during indomethacin-induced inflammation in the
murine jejunum in vitro
Abstract
Abstract Evidence exists that visceral afferent sensitivity is subject to regulatory mechanisms. We
hypothesized that afferent sensitivity is decreased in the small intestine during intestinal inflammation
by an inducible nitric oxide synthase (iNOS)-dependent mechanism. C57BL/6 mice were injected twice
with vehicle or 60 mg kg(-1) indomethacin subcutaneously to induce intestinal inflammation. Afferent
sensitivity was recorded on day 3 from a 2-cm segment of jejunum in vitro by extracellular multi-unit
afferent recordings from the mesenteric nerve bundle. In subgroups (n = 6), iNOS was inhibited
selectively by L-N6-(1-iminoethyl)-lysine (L-NIL) given either chronically from day 1-3 (3 mg kg(-1)
twice daily i.p.) or acutely into the organ bath (30 mumol L(-1)). The indomethacin-induced increase of
macroscopic and microscopic scores of intestinal inflammation (both P < 0.05) were unchanged after
pretreatment with L-NIL. Peak afferent firing following bradykinin (0.5 mumol L(-1)) was 55 +/- 8
impulse s(-1) during inflammation vs 97 +/- 7 impulse s(-1) in controls (P < 0.05). Normal firing rate
was preserved following L-NIL pretreatment (112 +/- 16 impulse s(-1)) or acute administration of
L-NIL (108 +/- 14 impulse s(-1)). A similar L-NIL dependent reduction was observed for 5-HT (250
mumol L(-1)) and mechanical ramp distension from 20 to 60 cmH(2)O (both P < 0.05). Intraluminal
pressure peaks were decreased to 0.66 +/- 0.1 cmH(2)O during inflammation compared to 2.51 +/- 0.3
in controls (P < 0.01). Afferent sensitivity is decreased by an iNOS-dependent mechanism during
intestinal inflammation which appears to be independent of the inflammatory response. This suggests
that iNOS-dependent nitric oxide production alters afferent sensitivity during inflammation by
interfering with signal transduction to afferent nerves rather than by attenuating intestinal inflammation.
Afferent nerve sensitivity is attenuated by an iNOS dependent mechanism 
during indomethacin-induced inflammation in the murine jejunum in vitro. 
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Abstract (250 words) 
Introduction: Evidence exists that visceral afferent sensitivity is subject to regulatory 
mechanisms. We hypothesized that afferent sensitivity is increased in the small intestine 
during intestinal inflammation by an iNOS dependent mechanism. 
Methods: C57BL/6 mice were injected twice with vehicle or 60 mgkg-1 indomethacin 
subcutaneously to induce intestinal inflammation. Afferent sensitivity was recorded on day 3 
from a 2 cm segment of jejunum in vitro by extracellular multi-unit afferent recordings from 
the mesenteric nerve bundle. In subgroups (n=6), the inducible NO-Synthase was selectively 
inhibited by L-N6-(1-iminoethyl)-lysine (L-NIL) given chronically from day 1-3 (3 mg kg-1 
twice daily i.p.) or acutely in the organ bath (30 µM). 
Results: Macroscopic and microscopic scores of intestinal inflammation were increased 
following indomethacin (both p<0.05) but unchanged during L-NIL administration. Peak 
afferent firing following bradykinin (0.5 µM) was 55±8 impsec-1 during inflammation 
compared to 97±7 impsec-1 in controls (p<0.05). This reduced discharge during inflammation 
was missing following chronic treatment with L-NIL (112±16 impsec-1) or its acute 
administration in the organ bath (108±14 impsec-1). A similar L-NIL dependent reduction 
observed for 5-HT (250 µM) and mechanical ramp distension from 20 to 60 cm H2O (both 
p<0.05). Intraluminal pressure peaks were decreased to 0.66±0.1 cmH2O during inflammation 
compared to 2.51±0.3 in controls (p<0.01). 
Conclusions: Afferent sensitivity is decreased by an iNOS dependent mechanism during 
intestinal inflammation which appears to be independent of the inflammatory response. This 
suggests that nitric oxide synthesis by iNOS alters afferent sensitivity during inflammation by 
interfering with signal transduction to afferent nerves rather than by attenuating the 
inflammatory response. 
 
Keywords: Inflammatory bowel disease, intestinal inflammation, nitric oxide, visceral 
  sensitivity 
Introduction 
An abundance of evidence was accumulated in recent years supporting the hypothesis that 
visceral hypersensitivity is the key pathophysiological mechanisms underlying functional 
bowel disorders such as functional dyspepsia and irritable bowel syndrome (1). This concept 
implies that in patients suffering from these disorders, physiological stimuli from the 
gastrointestinal tract that are not consciously perceived by healthy individuals are realized by 
diseased patients and sensed as pain and other abdominal symptoms. Thus, these patients 
seem to have a lowered sensory threshold for these physiological visceral stimuli or an 
increased sensory gain in the afferent autonomic nervous system or both (2). As a 
consequence, an enormous effort was undertaken worldwide, to identify mechanisms that 
regulate this afferent sensitivity in order to provide targets for therapeutic pharmacological 
intervention . 
 
While visceral sensory mechanisms attracted tremendous attention in the context of functional 
bowel disorders, regulation of sensation in the gastrointestinal tract is not limited to these 
disorders. Inflammatory bowel disease (IBD) is characterized by abdominal symptoms 
secondary to intestinal inflammation. The extent of inflammation often does not correlate well 
with the magnitude of the symptoms perceived by the patients (3) suggesting that regulation 
of sensory mechanisms may also occur during IBD. Indeed, Mayer et al. has shown in IBD 
patients that they have an increased threshold to visceral mechanical stimulation which was 
applied by balloon distension in the rectum (4). Thus, sensory mechanisms from the 
gastrointestinal tract appear to have the potential to be regulated in both ways. Upregulation - 
as seen in functional bowel disorders - may lower sensory thresholds for visceral stimuli, 
while downregulation may occur in the context of intestinal inflammation as seen during IBD 
(5). One strategy, therefore, to explore these mechanisms is to study models of intestinal 
inflammation in more detail rather than fucussing on models of hypersensitivity. 
 
One elegant way to elucidate mechanisms for the regulation of afferent sensitivity in the 
context of irritable bowel syndrome or intestinal inflammation is to directly record from 
mesenteric afferent nerves in rodents. In the DSS model of colitis, Coldwell et al. investigated 
mechanosensitivity and sensitivity to 5-HT by direct afferent nerve recordings. They observed 
increased afferent sensitivity of splanchnic afferents to 5-HT and the mast cell deganulator 
compound 48/80 during acute intestinal inflammation (6). Futhermore, Wynn et al. observed 
in the TNBs-colitis model that ATP has an enhanced role in mechanosensory transduction 
during inflammation (7). These studies were limited to experimental models of colitis 
representing only one part of the gut potentially afflicted during IBD since Crohn´s disease 
patients frequently have inflammation in the small intestine. Although it was shown  that ATP, 
5-HT and other mast cell mediators are at play when afferents are sensitized during intestinal 
inflammation, it remained unresolved, whether these mediators generally alter the visceral 
sensory threshold during inflammation.  
 
In our own work that involved a systemic LPS-induced inflammatory response, we found that 
nitric oxide synthesized by inducible nitric oxide synthase (iNOS, 8) seems to be one 
candidate which may have the potential to regulate intestinal afferent sensitivity during 
inflammation. This work, however, was based on a model simulating sepsis rather than 
intestinal inflammation, so that the prime question whether nitric oxide would also regulate 
afferent sensitivity during intestinal inflammation remained unresolved. 
 
We, therefore, chose a model of small intestinal inflammation that is established for the study 
of mechanisms contributing to inflammatory bowel disease (9). Our specific hypothesis was 
that afferent nerve discharge would be decreased during inflammation mediated via an iNOS 
dependent pathway independent of the extent of inflammation. 
 
Methods 
 
Animals 
Experiments were performed with male C57BL/6 mice (Charles River, Sulzfeld, Germany) 
weighing approximately 20g. Animals were kept under a 12h/12 h dark/light cycle and had 
free access to food and water until they were sacrificed. Animal experiments were approved 
by the local Institutional Review Board. 
 
Induction of intestinal inflammation 
Intestinal inflammation was induced by 2 subcutaneous injections of 60 mg kg-1 indomethacin 
at 8 a.m. on day 1 and day 2 (volume 1.5 ml kg-1; ethanol 100 % as vehicle). The timing and 
dose of indomethacin were determined considering previous reports in rat and by preliminary 
pilote experiments to ensure that a moderate intestinal inflammation was induced avoiding 
necrotic (black) intestine and limiting maximum letality to below 40 % of the animals. 
Control animals were injected with vehicle.  
 
Surgical procedure / Assessment of inflammation 
One day after the 2nd and last indomethacin/vehicle injection, animals were deeply 
anesthetized at 9 a. m. with isoflurane inhalation. Then, a laparotomy was performed and the 
small intestine exteriorized and inspected. Inflammation was quantified by a macroscopic 
inflammation score which included evaluation of adhesions, intestinal length, hyperemia and 
ulcers (range 0-8 points; Table 1a). This macroscopic score was previously published for rat 
by Yoshida (10) and modified in our study in order to be suitable for the evaluation of mice 
intestine as follows: "Intestinal shortening" was assessed instead of “wall thickness”. The 
description of ulcers was limited to "none", "single" or "multiple“, while the parameter 
"hyperemia" was amended by the category "intestinal bleeding". The appearance of the 
intestine was additionally photo-documented with a digital camera, so that the assessment 
could be double-checked later on. 
 
Furthermore, a segment of the jejunum just distal to the ligament of Treitz was excised, fixed 
in 4 % normal buffered formalin and processed for histology. Microscopic assessment of 
inflammation in this tissue was performed by a blinded observer on slides stained with 
haematoxylin and eosin. Inflammation was quantified with the help of a previously published 
microscopic score system (Table 1b, 11 ). 
 
Afferent nerve recording in vitro 
A segment of proximal jejunum with a length of 2 cm and the mesentery attached was 
carefully excised before the animal was killed with an overdose of isoflurane. Multi-unit 
afferent nerve recordings were established in a custom-made organ bath consisting of two 
chambers i. e. a perfusion and a recording chamber as published previously (12). The 
intestinal segment was placed into the perfusion chamber of the organ bath and superfused 
with Kreb´s buffer which was equilibrated with O2/CO2 mixture (composition of Kreb´s 
(mM): Na+ 143.5, K+ 5.9, Cl- 126, Ca2+ 2.5, Mg2+ 1.2, H2PO4 1.2, SO4 1.2, HCO3- 25, glucose 
10 and sodium butyrate 1, pH 7, superfused at a rate of 10 ml min-1, temperature 32°C). Both 
ends of the jejunal segment were cannulated and the lumen of the prepared segment was 
continuously perfused with Kreb´s from the proximal side of the jejunum (10 ml per hour), 
while the distal cannula remained open to the atmosphere during the experiment unless a 
mechanical ramp distension was performed (see below). Perfusion and luminal distension 
were performed with a syringe pump (IVAC 711, IVAC Corp, San Diego, USA). The 
intraluminal pressure was recorded continuously through a separate channel in the proximal 
cannula with a pressure transducer in order to monitor intestinal motor events (Neurolog 
pressure amplifier NL 108, Digitimer Ltd., Welwyn Garden City, UK). 
 
While the intestinal segment remained in the perfusion chamber, extracelluar multi-unit 
afferent nerve recordings were established by dissection of the mesenteric nerve out of the 
neurovascular mesenteric bundle under a viewing microscope (Wild, M3Z, Heerburg, 
Switzerland). For this purpose, the mesenteric arcade was drawn through a small aperture into 
a separate chamber of the organ bath next to the perfusion chamber i. e. the recording chamber. 
The aperture was sealed with vaseline and the separate recording chamber filled with 
colourless heavy liquid paraffin (Sigma Chemicals, Munich, Germany) pre-warmed to 32°C 
for electrical insulation. Under binocular microscopic vision, the dissected mesenteric nerve 
was placed onto one arm of a pair of bipolar platinum recording electrodes, while a strip of 
connective tissue was wrapped around the other arm. The electrodes were connected to a CED 
single channel 1902 preamplifier/filter (Cambridge Electronic Design (CED), Cambridge, 
UK). The signal was amplified 10,000 times and filtered with a bandwidth of 100 Hz to 1 kHz. 
Signals from the pressure transducer that recorded the intraluminal intestinal pressure were 
transmitted to another CED single channel 1902 preamplifier/filter. The output from the 1902, 
together with the signals from the pressure transducer were fed into a power Micro 1401 
interface system (CED) saved on the hard drive of a laptop computer, and viewed online by 
running Spike 2 software (version 4.01; CED). 
  
Protocol for afferent nerve recording 
Once a stable baseline recording was established for 20 minutes, the afferent nerve response 
to serosal 5-hydroxytryptamine (5-HT, 250µM), ramp distension up to 60 cmH2O and serosal 
bradykinin (BK, 0.5µM) were investigated.  For the afferent response to chemical stimuli, the 
perfusion was stopped and 5-HT or BK was administrated in the organ bath with a pipette 
(added volume 250 µl from a stock solution of 5 mM for 5-HT and 10 µM for BK, volume in 
the perfusion chamber of the organ bath was 5 ml; the minimal volume change by mediator 
administration was neglected). After 2 minutes the perfusion was started again to wash out the 
chemical. For continuous ramp distension, the outlet cannula in the intestinal lumen was 
clamped, while perfusion with Kreb´s solution was continued at 10 ml h-1. With this method 
the gut segment was distended to 60 cmH2O in approximately 90s. Then the cannula was 
opened to let intraluminal pressure return to baseline. After each stimulus an interval of at 
least 15 minutes was allowed to have the baseline discharge recovered before the next 
stimulus was administered. In preliminary cross-over pilot experiments, we had previously 
determined that there is no interaction with the different test stimuli concerning the afferent 
nerve response when administered in this order. Furthermore, doses of bradykinin and 5-HT 
were based on preliminary dose-finding studies to ensure that submaximal doses were chosen 
(data not shown). 
 
 
 
Experimental subgroups 
Afferent nerve recordings were obtained on day 3 after the beginning of different forms of 
pretreatment leading to 4 subgroups of animals (each n=6): 
1) Mice that were injected with indomethacin (60 mg kg-1 s.c.) on day 1 and 2 at 8 a.m. to 
induce intestinal inflammation. 
2) Mice that were injected with vehicle (100 % ethanol, volume 1.5 ml kg-1 s.c.) on day 1 and 
2 at 8 a.m. as controls for indomethacin induced inflammation. 
3) Mice that were injected with indomethacin (60 mg kg-1 s.c.) on day 1 and 2 at 8 a.m. to 
induce intestinal inflammation plus chronic treatment with the selective iNOS inhibitor L-N6-
(1-iminoethyl)-lysine (L-NIL). L-NIL was injected into the peritoneum at a dose of 3 mg kg-1 
(total volume 0.2 ml) at 8 a. m. and 8 p.m. on day 1 and 2 as well as on day 3 at 8 a. m. (total 
of 5 injections). Thus, the last dose was administered 1 hour before the intestinal segment was 
taken out for afferent nerve recordings. The dose of L-NIL was chosen according to previous 
publications (13, 14).  
4) Mice that were injected with indomethacin (60 mg kg-1 s.c.) on day 1 and 2 at 8 a.m. to 
induce intestinal inflammation. In this subgroup, L-NIL was dissolved in Kreb´s solution and 
administered at a concentration of 30 µM acutely in the organ bath 10 minutes prior to 
application of the test stimuli 5-HT, ramp distension and bradykinin. Again, this concentration 
of L-NIL was chosen according to a previously published report (15). 
 
In some additional control experiments, vehicle (ethanol) pre-treated mice received either 
intraperitoneal L-NIL chronically (as described in (3)) or actuely in the organ bath (as 
described in (4)). Neither intraperitoneal nor L-NIL administration in the organ bath altered 
afferent nerve discharge to 5-HT, luminal ramp distension or bradykinin in these additional 
control animals without intestinal inflammation (data not shown). 
 
 Drugs 
Indomethacin, L-NIL, 5-HT and bradykinin were purchased from Sigma, Munich, Germany. 
Isoflurane was obtained from Abbott, Wiesbaden, Germany. L-NIL was dissolved in normal 
saline for i.p. injection and in Kreb´s solution for perfusion in the organ bath. 5-HT and 
bradykinin were dissolved in normal saline. 
 
Data analysis 
The baseline discharge frequency (imp sec-1) was determined by averaging the afferent nerve 
discharge during the 2 minute recording period prior to administration of test stimuli. The 
afferent nerve response to chemical stimulation with 5-HT and BK was evaluated as the 
increase in peak impulse frequency per second above baseline discharge frequency during a 3 
second period of maximum afferent firing. The response to ramp distension was evaluated by 
quantifying the peak impulse frequency per second over a 3 second period at 10 cm H2O 
increments of intraluminal pressure until 60 cmH2O were reached. Intestinal motility was 
quantified at baseline by determining the mean of the pressure peaks during spontaneous 
phasic changes in intraluminal pressure for a 30 second interval before test stimuli were 
admimistered. Following the chemical stimuli BK and 5-HT, intestinal pressure events were 
quantified as the peak luminal pressure above baseline within 2 minutes after administration 
of the stimulus. Data are presented as mean ± SEM and were compared by one-way ANOVA 
and post-hoc Bonferroni correction. 
Results 
Intestinal inflammation 
Following indomethacin pretreatment, animals developed acute intestinal inflammation in the 
whole small intestine which was characterized by obvious intestinal dilation, marked 
reduction in small intestinal length and adhesions among small intestinal loops. Furthermore, 
intestinal inflammation was typically accompanied by hyperemia, ulcers of the gut wall and 
hemorrhage into the lumen. Elevated scores were observed with the macroscopic scoring 
system (see Table 1a) in animals pretreated with indomethacin compared to controls. After 
chronic pretreatment with the selective iNOS inhibitor L-NIL, intestinal inflammation was 
macroscopically not different from unpretreated animals. Figure 1A and B shows 
representative photographs and the macroscopic scores are given in Table 2. 
 
Intestinal inflammation was also assessed histologically in Haematoxylin & Eosin stains. 
Histology of inflamed intestine showed that the villi lost their normal upright fingerlike 
appearance. Villi were typically bent or tilted and further characterized by hyperemia and 
edema. The normal cellular architecture of the villi was destroyed. In some the erosion of the 
muscoal side was serious and many of the villi were absent (Figure 1C and D). After chronic 
pretreatment with the selective iNOS inhibitor L-NIL, intestinal inflammation was 
histologically not different from unpretreated animals. Details of the evaluation with a 
previously published score system (see Table 1b) is given in Table 2. 
 
Baseline afferent nerve discharge and motility 
Once the preparation for multi-unit afferent nerve recordings was established, continuous 
afferent firing was present at baseline which consisted of spikes with different amplitudes and 
waveforms. Baseline discharge was not different among the various subgroups (20±3.2 imp 
sec-1 in vehicle controls; 13±3.2 imp sec-1 after indomethacin pretreatment; 18±2.9 imp sec-1 
after indomethacin pretreatment plus chronic L-NIL; 19±3.4 imp sec-1 after indomethacin 
pretreatment plus acute L-NIL in the organ bath; all n=6, differences not significant). 
 
Spontaneous intestinal motor activity was observed in segments from control mice which was 
characterized by regular phasic contractions. This contractile pattern was not present in 
indomethacin pre-treated animals (Figure 2). The mean peak intraluminal pressure during two 
minutes recording period before administration was decreased from 2.51±0.3 cmH2O in 
controls to 0.66±0.1 cmH2O in indomethiacin pre-treated animals (p<0.05; n=6). In animals 
with inflamed small intestine secondary to indomethacin, additional chronic L-NIL pre-
treatment i. p. or acute L-NIL administration in the organ bath was followed by mean peak 
pressures of 0.80±0.1 cmH2O and 1.56±0.3 cmH2O which were also different from control 
animals (both p<0.05; n=6).  
 
Afferent nerve discharge to chemical and mechanical stimulation 
Afferent nerve discharge increased promptly following 5-HT administration into the organ 
bath at a concentration of 250 µM (Figure 2). The raw nerve trace revealed that this increased 
was generated by discharge of additional units that were recruited during the response and by 
spontaneously active fibers that increased their firing frequency. In vehicle controls maximum 
firing was 65±7.5 imp sec-1 above baseline, which was reduced to 32±3.3 imp sec-1 in animals 
with indomethacin induced inflammation (P<0.05). This reduction in afferent firing to 5-HT 
was not seen in animals with intestinal inflammation following chronic intraperitoneal pre-
treatment with L-NIL or after acute L-NIL administration in the organ bath (Figure 2D). As 
regards intestinal motility, 5-HT virtually abolished the regular motility pattern observed at 
baseline in control animals (Figure 2). Peak pressures were 2.62±0.4 cmH2O at baseline and 
1.59±0.2 cmH2O after 5-HT (p<0.05). Motor events were unchanged before and after 5-HT 
exposure in animals with inflamed small intestine (peak pressure 0.97±0.1 cmH2O before and 
1.08±0.1 cmH2O after 5-HT, n.s.). This situation was the same for chronic or acute L-NIL 
administration during intestinal inflammation (chronic L-NIL: peak pressure 1.16±0.18 
cmH2O before and 1.34±0.11 cmH2O after 5-HT, n.s.; acute L-NIL: peak pressure 1.48±0.3 
cmH2O before and1.52±0.2 cmH2O after 5-HT, n.s.). 
 
During mechanical stimulation by ramp distension a pressure dependent increase in afferent 
nerve discharge occurred in all experimental subgroups (Figure 3). When compared to 
controls, mechanical sensitivity was reduced during intestinal inflammation for luminal 
distension pressures that were exceeding 20 cmH2O (p<0.05, Figure 3D). At the maximum 
pressure of 60 cmH2O, afferent firing was 38±3.0 imp sec-1 in inflamed intestinal segments 
and 95±5.9 imp sec-1 in controls (p<0.05).  Peak afferent nerve discharge was unchanged 
during the complete mechanical ramp distension following chronic adminstration of the 
selective iNOS inhibitor L-NIL by repeated intraperitoneal injections or acute administration 
in the organ bath when compared to controls (Figure 3D). 
 
Bradykinin (BK) superfusion in the organ bath was followed by an obvious and robust 
increase in afferent nerve discharge (Figure 4). This increase consisted of new recruitment of 
previously silent units and increase firing frequency of spontaneously active fibers. While 
peak afferent firing was 97±7.0 imp sec-1 in intestinal segments from vehicle control animals, 
it declined to 55±7.9 imp sec-1 in inflamed segments after indomethacin pre-treatment (p<0.05, 
Figure 4D). Following pharmacological inhibition of iNOS during inflammation with the 
selective agent L-NIL administered either chronically (i.p.) or acutely in the organ bath, peak 
afferent firing was 112±16.0 imp sec-1 and 108±13.7 imp sec-1 which was not different from 
the response in uninflamed intestinal segments from vehicle control animals. 
 
In uninflamed intestinal segments from vehicle control animals, bradykinin was followed by 
an inhibition of regular phasic contractions (Figure 4) This was quantified by peak 
intraluminal pressures that were 1.68 ± 0.3 cmH2O before and 2.1 ± 0.4cmH2O after 
bradykinin superfusion (n.s.). The motor response to bradykinin was different in inflamed 
intestinal segments from indomethacin pre-treated animals. Here, phasic intestinal 
contractions were virtually absent before bradykinin administration but a single tonic rise in 
intraluminal pressure was observed which occurred obviously unrelated to the peak increase 
in afferent firing. This tonic pressure peak was 6.7±2.4 cmH2O in inflamed segments 
compared to the intraluminal pressure of 0.9±0.1 cmH2O at baseline (p < 0.001). The tonic 
increase in intraluminal pressure following bradykinin compared to baseline was also 
observed in inflamed intestinal segments following chronic L-NIL pre-treatment i.p. which 
was 1.1±0.1 cmH2O before and 5.4±0.4 cmH2O (p<0.001), and following acute 
administration of L-NIL into the organ bath 1.4 ± 0.2 cmH2O before and 8.9 ± 1.0cm H2O 
after acute L-NIL administration (p<0.001). 
Discussion 
 
In the present study, alterations in afferent sensitivity were investigated at the level of the 
mesenteric nerve during small intestinal inflammation induced by indomethacin in mice 
which was previously described as a model for inflammatory bowel disease (9, 16). Peak 
afferent firing to mechanical ramp distension of the intestinal loop and to chemical 
stimulation by superfusion with bradykinin or 5-HT in the organ bath in vitro was attenuated 
during inflammation compared to control animals. Hyporesponsiveness of the afferent nerve 
during intestinal inflammation was reversed to control levels following pretreatment with the 
selective iNOS inhibitor L-NIL. This was observed for both chronic L-NIL administration 
with repeated intraperitoneal injections during the induction phase of inflammation and acute 
L-NIL administration in the organ bath 10 minutes prior to chemical or mechanical 
stimulation. Interestingly, chronic L-NIL pretreatment did not attenuate the extent of intestinal 
inflammation following indomethacin which was quantified by a macroscopic and 
microscopic scoring system. Spontaneous intestinal motility was virtually absent in the jejunal 
segment during inflammation which was also uninfluenced by previous L-NIL pretreatment.  
 
Inflammation develops in the intestine following indomethacin administration since the 
mucosa is depleted of prostaglandins (17, 18). Subsequently, ulcers and increased intestinal 
permeability develop that allows luminal contents such as bacterial wall components (e.g. 
lipopolysaccharides) to invade the intestinal wall with a subsequent development of 
inflammation (16, 19, 20, 21). These trigger an acute phase response including the release of 
proinflammatory cytokines which subsequently entertain the intestinal inflammatory response 
that was described in this study and also characterized by others (16, 21). It is of note that 
although indomethacin induced intestinal inflammation was described as a model for 
inflammatory bowel disease (9), it represents this disease entitiy only to a limited extent. 
Limiting factors are in particular that the inflammation develops subsequent to depletion of 
prostaglandin, while increased prostaglandin production is a feature of inflammatory bowel 
disease in humans (22, 23), and that inflammation was studied after several days so that it 
may lack typical features of chronic inflammation. Nevertheless, this model was chosen since 
we aimed to study afferent nerve sensitivity in the small intestine and relatively few models 
with intestinal inflammation are available to induce inflammation in this part of the gut (9). 
Furthermore, our focus was to study modulation of afferent sensitivity during intestinal 
inflammation mainly to learn more about modulatory mechanisms of afferent sensitivity in 
general rather than to investigate a specific aspect of inflammatory bowel disease. 
 
One of the most intriguing findings in the present study is that afferent sensitivity was reduced 
during small intestinal inflammation which was secondary to indomethacin pretreatment. This 
is in contrast to other reports on visceral sensitivity in different experimental models of 
intestinal inflammation (6, 7, 24). One difference is that previous reports investigated mostly 
the intrinsic and extrinsic sensory innervation during colitis, while our study was on small 
intestinal inflammation. It appears rather unlikely, however, that mechanisms of afferent 
sensitivity during inflammation are fundamentally different in the small and large intestine, so 
that the observed hyposensitivity is more likely to be secondary to the specific alterations in 
intestinal homeostasis following indomethacin administration rather than regional differences. 
Simple destruction of afferent nerve terminals can be ruled out as an explanation since the 
reduced sensitivity was pharmacologically reversible with the iNOS inhibitor L-NIL. Non-
steroidal antiinflammatory drugs entail depletion of prostaglandins in the intestinal mucosa 
(17, 18). As prostanoids have the potential to sensitize intestinal afferents (25), it appears to 
be the most likely explanation that their general depletion led to the overall reduced visceral 
sensitivity during indomethacin induced inflammation in this study. Alternatively, the 
developing intestinal inflammation may have been accompanied by a downregulation of 
afferent sensitivity via a different mechanism. Considering our previous work with a systemic 
model of LPS induced inflammation, intestinal inflammation may have induced the synthesis 
of iNOS with the subsequent release of nitric oxide as a potential mechanism to reduce 
afferent sensitivity to other stimuli as shown in the systemic LPS model (8). Thus, this 
mechanism was further investigated. 
 
We found that attenuated afferent sensitivity following intestinal inflammation was 
reestablished to control levels following chronic administration of L-NIL, while inflammation 
developed. One possible explanation, why afferent sensitivity was reestablished to control 
levels is that inhibition of iNOS by L-NIL simply attenuated the inflammatory response 
brought on by indomethacin. Indeed, iNOS induction was described in several reports during 
indomethacin induced intestinal inflammation as a potential consequence of the increase in 
intestinal permeability (18, 20) that exposes the gut wall to bacterial cell wall components 
such as LPS. Several reports suggest that inhibition of iNOS by L-NIL improves the 
inflammatory response (26, 27). This proinflammatory action of nitric oxide synthesized by 
iNOS was questioned by other studies suggesting that nitric oxide from iNOS may also have 
protective effects e.g. in septic shock or gastric ulcer disease (28, 29). Consequently, it is not 
clear from previous work whether chronic L-NIL treatment would have a beneficial effect on 
indomethacin induced intestinal inflammation. We, therefore, quantified intestinal 
inflammation by two scoring systems and found that L-NIL did not alter the inflammatory 
response. Thus, reduced intestinal inflammation is unlikely to explain the attentuated afferent 
sensitivity following L-NIL pretreatment in animals with intestinl inflammation. Nitric oxide 
synthesized by iNOS rather seems to have the potential to downregulate afferent sensitivity 
during intestinal inflammation without attenuation of the inflammatory response. A potential 
pitfall of assessing inflammation by score systems is that specific aspects of the inflammatory 
response such as altered infiltration with different subset of inflammatory cells etc. may have 
been missed, rendering the above mentioned interpretation questionable. This interpretation, 
however, is nevertheless further supported by the observation that acute administration in the 
organ bath 10 minutes prior to recording afferent sensitivity had the same effect i.e. a 
reconstitution of afferent sensitivity to the level of uninflamed intestine when compared to 
intestinal inflammation. It is extremly unlikely that administration of L-NIL 10 minutes prior 
to recordings affected the inflammatory response in the intestine that was going on for more 
than 48 hours at that time. In addition to a potentially altered inflammatory response, changes 
in intestinal motor events to 5-HT and BK following L-NIL were ruled out by luminal 
pressure recordings as they may indirectly affected afferent sensitivity by stimulation of 
mechanosensitive afferents. Both experimental conditions together, i.e. chronic and acute L-
NIL treatment, therefore, support the interpretation that an iNOS dependent downregulation 
of afferent sensitivity occurred during intestinal inflammation. 
 
The obvious question arising from these observations is by which mechanism nitric oxide 
downregulates afferent sensitivity. 5-HT and BK have different mechanisms of sensitizing 
intestinal afferents i.e. ligand-gated ion channels for 5-HT (5-HT3 receptor, 30) and G-coupled 
proteins for BK (31). Furthermore, luminal ramp distension sensitizes an array of different 
mechanosensitive afferent of different origin which are low-threshold, high-threshold and 
wide-dynamic range mechanosensitive afferents (32). Since afferent firing to all these stimuli 
was attenuated by intestinal inflammation and reversed by L-NIL pretreatment, it appears 
unlikely that nitric oxide synthesized from iNOS affected these different mechanisms directly, 
although it has a potential to alter the G-protein mechanism as well as to alter the conductance 
of ion channels by S-nitrosylation (33, 34). It rather seems that nitric oxide attenuates overall 
afferent sensitivity and this would imply a common underlying mechanism. Indeed, nitric 
oxide was shown to have an inhibitory action on enteric neurons, visceral and somatic 
afferents signaling through increased production of the second messenger guanosine 3',5'-
cyclic monophosphate (cGMP ) (35, 36, 37) which we suggest to be the most likely 
mechanism to underly the observed attenuated afferent sensitivity during intestinal 
inflammation in our study. 
 
We conclude that nitric oxide synthesized by iNOS during indomethacin induced intestinal 
inflammation may attenuate signal transduction to extrinsic sensory nerves without altering 
the inflammatory response. Nitric oxide, therefore, may represent a mechanism that allows the 
adaptation of visceral sensitivity to continued intestinal inflammation. Whether this 
mechanisms explains reduced visceral sensitivity in patients suffering from inflammatory 
bowel disease remains to be elucidated by further pharmacological studies. 
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Table 1a Score system for macroscopic inflammation (modified after reference D29) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1b Score system for histological assessment of inflammation (see also reference D30) 
 
 
 
 
 
 
 
 
 
 
 
 
Adhesions (serosa and mesentery)       
     None 0 
     Minimal 1 
     Involving several loops 2 
Intestinal shortening  
     None 0 
     Recognized 1 
     Severe 2 
Hyperemia  
     None 0 
     Recognized 1 
     Luminal bleeding 2 
Ulcers  
     None 0 
     Single Ulcer 1 
     Multiple 2 
Epithelium         
     Normal morphology 0 
     Loss of goblet cells 1 
     Loss of goblet cells in large areas 
     Loss of crypts 
     Loss of crypts in large areas 
2 
3 
4 
Infiltration  
     No infiltrates 0 
     Infiltrate around crypt basis 
     Infiltrate reaching to L. muscularis mucosae 
1 
2 
     Extensive infiltration reaching the 
     L. muscularis mucosae and thickening of  
     mucosa with severe oedema 
     Infiltration of the L. submucosa   
3 
 
 
4 
Table 2 
 
experimental group macroscopic score histology score 
vehicle control (n=5) 0,2 ± 0,20 1,6 ± 0,60 
vehicle plus L-NIL (n=3) 0,33 ± 0,33  2,0 ± 0,58 
inflammation (n=5) 4,8 ± 0,74* 4,6 ± 0,51* 
inflammation plus L-NIL 
treatment (n=4) 
 
4,0 ± 0,71* 
 
4,0 ± 1,08* 
 
 
Indomethacin induced intestinal inflammation was assessed by macroscopic and microscopic 
scoring systems in separate experiments (D29, D30). To evaluate a potential effect of the 
selective iNOS inhibitor L-NIL on intestinal inflammation, it was administered chronically by 
repeated intraperitoneal injections (3 mg kg-1). For details see methods. Note that L-NIL 
administration did not alter the intestinal tissue neither in the uninflamed (vehicle plus L-NIL 
versus vehicle control) nor in the inflamed condition (inflammation versus inflammation plus 
L-NIL treatment). Both subgroups with inflammation were different compared to vehicle 
control (*p<0.05). 
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Figure 1 
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Photographs illustrating the macroscopic appearance of control (A) and inflamed (B) intestine 
after indomethacin treatment. The lower two images show representative histology from 
control (C) and indomethacin treated (D) small intestine (hematoxylin & eosin stains). Note 
the moderate macroscopic inflammation characterized by edema and shortening of the 
intestine, while histological examination reveals substantial alterations in the villous 
architecture and integrity (scale bar is ***µm). 
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Representative recordings of afferent nerve discharge to 5-HT (250µM) given in the organ 
bath. A: recording from a vehicle control animal withouth intestinal inflammation. B: 
response to 5-HT in an animal with indomethacin induced intestinal inflammation. C: 
Intestinal inflammation plus chronic L-NIL pretreatment. The upper traces showed the raw 
nerve recording before and after 5-HT administration, while middle traces display sequential 
rate histograms of mesenteric afferent nerve discharge frequency in 3 seconds bin-size as used 
for analysis (?). The lower traces give the luminal pressure in the jejunum. Panel D 
summarizes the afferent nerve discharge minus baseline per second in each experimental 
group including recordings from segments of animals with intestinal inflammation that 
received acute L-NIL administration  in the organ bath (30 µM). Data on the intestinal motor 
response is given in the text. Note that both chronic i.e. repeated i.p. treatment with the 
selective iNOS inhibitor L-NIL (3 mg kg-1) and its acute administration in the organ bath 
reversed the reduced afferent nerve discharge during intestinal inflammation when compared 
to vehicle controls ( all n=6, mean±SEM; p<0.05 versus control). 
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Figure 3 Representative recordings of afferent nerve discharge to luminal ramp distension. A: 
recording from a vehicle control animal withouth intestinal inflammation. B: response in an 
animal with indomethacin induced intestinal inflammation. C: Intestinal inflammation plus 
chronic L-NIL pretreatment. The upper traces showed the raw nerve recording, while middle 
traces display sequential rate histograms of mesenteric afferent nerve discharge frequency in 3 
seconds bins (as used for analysis). The lower traces give the luminal pressure in the jejunum. 
Panel D summarizes the afferent nerve discharge minus baseline per second in each 
experimental group including recordings from segments of animals with intestinal 
inflammation that received acute L-NIL administration in the organ bath (30 µM). Note that 
both chronic i.e. repeated i.p. treatment with the selective iNOS inhibitor L-NIL (3 mg kg-1) 
and its acute administration in the organ bath reversed the reduced afferent nerve discharge 
during intestinal inflammation when compared to vehicle controls (all n=6, mean±SEM; 
p<0.05 versus control). 
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Representative recordings of afferent nerve discharge to BK (0.5 µM) given in the organ bath. 
A: recording from a vehicle control animal withouth intestinal inflammation. B: response in 
an animal with indomethacin induced intestinal inflammation. C: Intestinal inflammation plus 
chronic L-NIL pretreatment. The upper traces showed the raw nerve recording before and 
after BK administration, while middle traces display sequential rate histograms of mesenteric 
afferent nerve discharge frequency in 3 seconds bin-size as used for analysis (?). The lower 
traces give the luminal pressure in the jejunum. Panel D summarizes the afferent nerve 
discharge minus baseline per second in each experimental group including recordings from 
segments of animals with intestinal inflammation that received acute L-NIL administration  in 
the organ bath (30 µM). Data on the intestinal motor response is given in the text. Note that 
both chronic i.e. repeated i.p. treatment with the selective iNOS inhibitor L-NIL (3 mg kg-1) 
and its acute administration in the organ bath reversed the reduced afferent nerve discharge 
during intestinal inflammation when compared to vehicle controls (all n=6, mean±SEM; 
p<0.05 versus control). 
 
 
